



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 30, 2020

Peter Hecht, Ph.D.
Chief Executive Officer
Cyclerion Therapeutics, Inc.
301 Binney Street
Cambridge, MA, 02142

Re: Cyclerion Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 24, 2020
File No. 333-240095

Dear Dr. Hecht:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason L. Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Gary J. Simon, Esq.